VEGFA and Thromboembolism: This favourable systemic safety profile is of particular importance for the NV-AMD population that is at higher risk for cardiovascular and thromboembolic diseases.28 In conclusion, 3 years of continuous selective VEGF inhibition with pegaptanib sodium in the treatment of patients with NV-AMD confirmed the favourable safety profile of pegaptanib sodium.